[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367068-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367068-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","lgr5-an-emerging-therapeutic-target-for-cancer-metastasis-and-chemotherapy-resistance","LGR5 - An emerging therapeutic target for cancer metastasis and chemotherapy resistance","","Cancer stem cells drive tumor progression, recurrence, and chemotherapy resistance, and Leucine-rich G repeat-containing protein-coupled receptor 5 (LGR5) has emerged as a cancer stem cell marker across multiple malignancies. This review synthesizes evidence on LGR5 expression, functional roles, and the molecular pathways regulated by LGR5, emphasizing links to migration, invasion, metastasis, angiogenesis, and chemoresistance. It also discusses therapeutic prospects for inhibiting LGR5 while noting context-dependent pro- or anti-tumor signaling effects.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/lgr5-an-emerging-therapeutic-target-for-cancer-metastasis-and-chemotherapy-resistance/367068/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/lgr5-an-emerging-therapeutic-target-for-cancer-metastasis-and-chemotherapy-resistance/367068.png","ImageObject",300,407,{"name":42,"@type":43},"Finn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role do cancer stem cells play in chemotherapy resistance and recurrence?","Question",{"text":63,"@type":64},"Cancer stem cells support tumor progression and contribute to chemotherapy resistance and recurrence by maintaining tumor growth, surviving treatment stress, and repopulating tumors after therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is LGR5 linked to cancer development and metastasis?",{"text":68,"@type":64},"LGR5 is described as a cancer stem cell marker involved in pathways such as WNT/β-catenin and is associated with promoting migration, invasion, metastasis, and angiogenesis in several cancer types.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is targeting LGR5 considered promising but complex?",{"text":72,"@type":64},"The review states that inhibiting LGR5 may provide an anti-cancer strategy, yet functional outcomes can vary by cancer type, tumor microenvironment, and interactions with other molecules in the LGR5 signaling pathway.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367068,1790522815,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Cancer and Metastasis Reviews (2025) 44:23  \n[https://doi.org/10.1007/s10555-024-10239-x](https://doi.org/10.1007/s10555-024-10239-x)  \nLGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance  \nWanqi Wang1 · Noor A. Lokman1 · Simon C. Barry1,2 · Martin K. Oehler1,3 · Carmela Ricciardelli1  \nReceived: 23 July 2024 / Accepted: 24 December 2024 / Published online: 17 January 2025 © The Author(s) 2025  \nAbstract  \nCancer stem cells play an important role in tumor progression and chemotherapy resistance. Leucine-rich G repeat-containing protein-coupled receptor 5 (LGR5) has been identified as a cancer stem cell marker in several cancer types. LGR5 is involved in cancer development and progression via several pathways including WNT/β-catenin signaling pathway. LGR5 plays a role in tumor progression by promoting cancer cell migration, invasion, metastasis, and angiogenesis in many cancers including colorectal, brain, gastric, and ovarian cancer. This review summarises the current knowledge on the expression and functional role of LGR5 in cancers, the molecular mechanisms regulated by LGR5, and the relationship between LGR5 and chemotherapy resistance. The review also includes highlights potential strategies to inhibit LGR5 expression and function. The majority of functional studies have shown that LGR5 plays an important role in promoting cancer progression, metastasis and chemotherapy resistance however, in some contexts LGR5 can also activate tumor-suppressive pathways and LGR5 negative cells can also promote cancer progression. The review highlights that targeting LGR5 is a promising anti-cancer treatment but the functional effect of LGR5 on tumor cells is complex may be dependent on cancer type, tumor microenvironment and cross-talk with other molecules in the LGR5 signaling pathway.  \nKeywords LGR5 · WNT/β-catenin · Metastasis · Chemoresistant  \n* Carmela Ricciardelli [carmela.ricciardelli@adelaide.edu.au](carmela.ricciardelli@adelaide.edu.au)  \nWanqi Wang  \n[wanqi.wang@adelaide.edu.au](wanqi.wang@adelaide.edu.au)  \nNoor A. Lokman  \n[noor.lokman@adelaide.edu.au](noor.lokman@adelaide.edu.au)  \nSimon C. Barry  \n[Simon.barry@adelaide.edu.au](Simon.barry@adelaide.edu.au)  \nMartin K. Oehler  \n[Martin.oehler@adelaide.edu.au](Martin.oehler@adelaide.edu.au)  \n1 Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide 5005, Australia  \n2 Molecular Immunology, Robinson Research Institute, University of Adelaide, Adelaide 5005, Australia  \n3 Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide 5000, Australia  \n1 Introduction  \nCancer continues to be one of the most difficult diseases to combat globally, despite extensive research and recent advancements in systemic treatments. Generally, the majority of cancer-related deaths are due to tumor recurrence and metastasis [1] . Thus, it is crucial to have deeper understanding of the cellular and molecular mechanisms that drive cancer recurrence and spread.  \nCancer stem cells (CSCs) are tumor-initiating or propagating cells that play a role in tumor progression, chemotherapy resistance, and recurrence [2, 3] . CSCs have unique ability to self-renew and differentiate, forming diverse cell populations within tumors. CSCs are central to cancer progression due to their capacity to maintain tumor growth and contribute to its heterogeneity [4]. It is widely believed that CSCs are involved in cellular reprogramming during oncogenic transformation, and drugs targeting CSCs will inhibit cancer progression and tumor self-renewal [2] . CSCs are pro-tumorigenic and have been identified in several malignancies [2 , 5] . Chemotherapy resistance is a major challenge in cancer treatment, and CSCs are more resilient to  \nchemotherapeutic agents due to several mechanisms. These include the overexpression of ATP-binding cassette (ABC) transporters, which pump drugs out of the cells, enha","cbCaij84M07uL8TR","https://ap.wps.com/l/cbCaij84M07uL8TR","pdf",1238251,23,"English","# Abstract\n# Keywords\n# Introduction\n# LGR5 structure and function","[{\"question\":\"What role do cancer stem cells play in chemotherapy resistance and recurrence?\",\"answer\":\"Cancer stem cells support tumor progression and contribute to chemotherapy resistance and recurrence by maintaining tumor growth, surviving treatment stress, and repopulating tumors after therapy.\"},{\"question\":\"How is LGR5 linked to cancer development and metastasis?\",\"answer\":\"LGR5 is described as a cancer stem cell marker involved in pathways such as WNT/β-catenin and is associated with promoting migration, invasion, metastasis, and angiogenesis in several cancer types.\"},{\"question\":\"Why is targeting LGR5 considered promising but complex?\",\"answer\":\"The review states that inhibiting LGR5 may provide an anti-cancer strategy, yet functional outcomes can vary by cancer type, tumor microenvironment, and interactions with other molecules in the LGR5 signaling pathway.\"}]","LGR5 - An emerging therapeutic target for cancer metastasis and chemotherapy resistance | PDF",1790169129,58,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a85c43b6f16cf06d56c8578930d3d60a.webp",983,1305,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8515bd0bb932102c39339471739578f.webp",982,1304,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/273f55bb84514804390316c15dd69496.webp",981,1303,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a70f12ad6dcacfae79db4a2fc4ffc2f9.webp",980,1301]